Vir Biotechnology ( (VIR) ) has issued an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively. The data showed compelling early clinical responses and a favorable safety profile, with no dose-limiting toxicities and no severe cytokine release syndrome observed. The findings support the potential of Vir’s PRO-XTEN masking technology to improve treatment efficacy and tolerability, which could lead to novel therapeutic options for cancer patients.
More about Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on harnessing the immune system to transform the treatment of serious infectious diseases and cancer. Its portfolio includes programs targeting chronic hepatitis infections and various solid tumors using dual-masked T-cell engagers, with a preclinical pipeline addressing both infectious diseases and oncologic malignancies.
YTD Price Performance: 8.53%
Average Trading Volume: 1,290,800
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.09B
For an in-depth examination of VIR stock, go to TipRanks’ Stock Analysis page.
